Molecular Biomarker-guided Anti-angiogenic Targeted Therapy for Malignant Glioma

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2019 Jun 19

PMID 31210419

Citations 10

Authors

Chengrui Yan

Jiaru Wang

Yuyan Yang

Wenbin Ma

Xiaolin Chen

Affiliations

Soon will be listed here.

Abstract

Despite aggressive multimodality treatment, the prognosis of glioma, especially malignant glioma, remains very poor. After decades of effort, anti-angiogenic therapy has become an important method of cancer treatment in addition to surgery, radiotherapy and chemotherapy. Although the performance of anti-angiogenic therapy in colorectal cancer is good, its performance in malignant glioma remains unsatisfactory. Several phase III clinical trials showed no overall survival benefits. To solve this problem, the division of patients into groups based on their molecular biomarkers is an important step. This paper provides current insights into anti-angiogenic drugs undergoing clinical trials and discusses the potential of molecular biomarkers to guide glioma diagnosis.

Citing Articles

PBX3 as a biomarker for the early diagnosis and prediction of prognosis of glioma.

Pan C, Bai X, Li N, Zheng N, Si Y, Zhao Y PLoS One. 2024; 19(2):e0293647.

PMID: 38324550 PMC: 10849273. DOI: 10.1371/journal.pone.0293647.

TRIM47 promotes glioma angiogenesis by suppressing Smad4.

Wang Z, Li Z, Han C, Cheng Y, Wang K In Vitro Cell Dev Biol Anim. 2022; 58(9):771-779.

PMID: 36203070 DOI: 10.1007/s11626-022-00722-6.

Efficacy and safety of bevacizumab combined with temozolomide in the treatment of recurrent malignant gliomas and its influence on serum tumor markers.

Lei J, Zhou Z Am J Transl Res. 2022; 13(12):13886-13893.

PMID: 35035729 PMC: 8748084.

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.

Jiguet-Jiglaire C, Boissonneau S, Denicolai E, Hein V, Lasseur R, Garcia J Acta Neuropathol Commun. 2022; 10(1):1.

PMID: 34980260 PMC: 8722051. DOI: 10.1186/s40478-021-01305-4.

Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma.

Fang D, Huang W, Cheng G, Liu X, Liu S, Hou B J Oncol. 2022; 2021:1827992.

PMID: 34976054 PMC: 8718316. DOI: 10.1155/2021/1827992.

References

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

Kreisl T, Kotliarova S, Butman J, Albert P, Kim L, Musib L . A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 2010; 12(2):181-9. PMC: 2940576. DOI: 10.1093/neuonc/nop042. View

Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A . Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol. 2013; 16(3):392-9. PMC: 3922517. DOI: 10.1093/neuonc/not226. View

Verma R, Hansch C . Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem. 2007; 15(6):2223-68. DOI: 10.1016/j.bmc.2007.01.011. View

Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot O . Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. J Clin Oncol. 2015; 33(25):2735-44. PMC: 5015426. DOI: 10.1200/JCO.2015.61.5005. View

Brem S . The role of vascular proliferation in the growth of brain tumors. Clin Neurosurg. 1976; 23:440-53. DOI: 10.1093/neurosurgery/23.cn_suppl_1.440. View

Yan C, Wang J, Yang Y, Ma W, Chen X . Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma. J Cell Mol Med. 2019; 23(8):4876-4882. PMC: 6653115. DOI: 10.1111/jcmm.14417. View

Folkman J . Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov. 2007; 6(4):273-86. DOI: 10.1038/nrd2115. View

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

10.

Nabors L, Fink K, Mikkelsen T, Grujicic D, Tarnawski R, Nam D . Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015; 17(5):708-17. PMC: 4482861. DOI: 10.1093/neuonc/nou356. View

11.

Teicher B . Antiangiogenic agents and targets: A perspective. Biochem Pharmacol. 2010; 81(1):6-12. DOI: 10.1016/j.bcp.2010.09.023. View

12.

Cao Y, Langer R . A review of Judah Folkman's remarkable achievements in biomedicine. Proc Natl Acad Sci U S A. 2008; 105(36):13203-5. PMC: 2533169. DOI: 10.1073/pnas.0806582105. View

13.

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

14.

Odia Y, Iwamoto F, Moustakas A, Fraum T, Salgado C, Li A . A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. J Neurooncol. 2015; 127(1):127-35. DOI: 10.1007/s11060-015-2020-x. View

15.

Reardon D, Nabors L, Stupp R, Mikkelsen T . Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008; 17(8):1225-35. PMC: 2832832. DOI: 10.1517/13543784.17.8.1225. View

16.

Siegal T, Charbit H, Paldor I, Zelikovitch B, Canello T, Benis A . Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab. J Neurosurg. 2016; 125(4):1008-1015. DOI: 10.3171/2015.8.JNS15437. View

17.

Urup T, Michaelsen S, Olsen L, Toft A, Christensen I, Grunnet K . Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Mol Oncol. 2016; 10(8):1160-8. PMC: 5423207. DOI: 10.1016/j.molonc.2016.05.005. View

18.

Gravendeel L, Kouwenhoven M, Gevaert O, de Rooi J, Stubbs A, Duijm J . Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009; 69(23):9065-72. DOI: 10.1158/0008-5472.CAN-09-2307. View

19.

Hayes J, Thygesen H, Gregory W, Westhead D, French P, van den Bent M . A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Mol Oncol. 2016; 10(8):1296-304. PMC: 5423205. DOI: 10.1016/j.molonc.2016.06.004. View

20.

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V . Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27(8):1227-34. DOI: 10.1200/JCO.2007.14.5466. View